Nektar Therapeutics Annual Income Statement (NASDAQ:NKTR)

Add to My Stocks
$22.53 $0.36 (1.57%) NKTR stock closing price Mar 23, 2017 (Closing)

NKTR stock valuation based on fundamental analysis involves checking and analyzing financial statements and not just the Nektar Therapeutics stock price. In the income statement, an investor can check for important parameters like the topline, the bottomline, the EPS basic, dividends etc. The income statement is generated for a specific period of time. The revenue increase of $230.78M for 2015 impacts the NKTR stock. Investors typically check year over year or quarter over quarter revenue growth. One also needs to look at Nektar Therapeutics assets, operating expenses and Nektar Therapeutics free cash flow. The profit and loss statement shows revenue of $230.78M for 2015. Revenue has grown by $30.08M YoY for NKTR stock. Nektar Therapeutics revenue for 2015 is $230.78M. View revenue and profit details for latest and last 10 financial years.

show more
Annual
Quarterly
View Previous Years
View Next Years
Fiscal year is Jan - Dec. 2015 2014 2013 2012 2011 2010 2009 2008 2007
Nektar Therapeutics Net Sales or Revenues
230.78M200.7M148.92M81.19M71.48M159.03M71.93M90.18M273.02M
Cost Of Goods Sold (COGS)34.1M28.53M38.5M30.42M21.89M25.66M30.94M35.03M147.51M
Nektar Therapeutics Gross Profit
196.68M172.17M110.41M50.76M49.58M133.37M40.98M55.14M125.51M
Research & Development Expense182.78M147.73M190.01M148.67M126.76M108.06M95.1M154.41M153.57M
Selling General & Admin Expense43.26M40.92M40.53M43.28M46.76M53.56M41M-16.61M56.33M
Income Before Depreciation Depletion Amortization-29.37M-16.48M-120.13M-141.2M-123.93M-28.25M-95.13M-82.65M-84.4M
Depreciation Depletion Amortization--------0.94M
Non Operating Income-12.39M0.81M1.12M3.29M1.2M2.37M4.53M62.7M72.53M
Interest Expense38.9M38.75M40.76M33.54M10.22M11.17M12.17M15.19M18.63M
Nektar Therapeutics Pretax Income
-80.67M-54.42M-159.76M-171.44M-132.96M-37.05M-102.77M-35.14M-31.45M
Provision for Income Taxes0.5M-0.51M2.24M0.4M1.01M0.88M-0.25M-0.8M1.3M
Minority Interest---------
Investment Gains Losses---------
Other Income---------
Income Before Extraordinaries & Disc Operations-81.17M-53.91M-162.01M-171.85M-133.97M-37.93M-102.51M-34.33M-32.76M
Extraordinary Items & Discontinued Operations---------
Nektar Therapeutics Net Income (Profit/Loss)
-81.17M-53.91M-162.01M-171.85M-133.97M-37.93M-102.51M-34.33M-32.76M
Average Shares used to compute Diluted EPS132.46M126.87M115.73M114.82M112.94M94.08M92.77M92.41M91.88M
Average Shares used to compute Basic EPS132.46M126.87M115.73M114.82M112.94M94.08M92.77M92.41M91.88M
Income Before Nonrecurring Items-81.18M-53.92M-162.01M-170.77M-133.98M-25.71M-102.52M-154.01M-83.29M
Income from Nonrecurring Items----1.09M--12.23M-69.57M50.53M
Nektar Therapeutics Earnings Per Share Basic Net
-0.61-0.42-1.40-1.50-1.19-0.40-1.11-0.37-0.36
Nektar Therapeutics Earnings Per Share Diluted Net
-0.61-0.42-1.40-1.50-1.19-0.40-1.11-0.37-0.36
EPS Diluted Before Nonrecurring Items-0.61-0.42-1.40-1.49-1.19-0.27-1.11-1.67-0.91
Preferred Dividends Acc Pd---------
Dividends Common---------
Dividend Per Share Common---------
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years
Get Income statement for another ticker

1:22
NKTR
The key things to look for in an income statement while doing Nektar Therapeutics stock analysis are:
  • Topline: A growing topline, as seen from the Nektar Therapeutics revenue chart, as is the case with Nektar Therapeutics indicates a growing business. One needs to compare the QoQ or YoY topline growth of NKTR stock with its peers like SAGE stock and IRWD stock to see if the growth compares well with what can be expected for a company in that industry.
  • Bottom line: The word bottom line comes because it is usually the last line of the income statement and refers to the actual profits after deducting all expenses from the revenues. NKTR stock had a healthy bottom line growth.
The income statement is also called the profit and loss statement. Apart from the income statement, one can check the Nektar Therapeutics historical stock prices to check how the price has moved with time. .

Nektar Therapeutics Income Statement - Key Financial Ratios

PS ratio (
price sales ratio
)
20.3007
Operating margin
-90.5
Net profit margin
-118.9
Dividend yield
0%